22 June 2023 
EMA/CHMP/263819/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Lonsurf 
trifluridine / tipiracil 
On 22 June 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Lonsurf. The marketing authorisation holder for this medicinal product is Les Laboratoires Servier. 
The CHMP adopted a new indication for the third-line treatment of colorectal cancer in combination with 
bevacizumab. For information, the full indications for Lonsurf will therefore be as follows:2  
Colorectal cancer 
Lonsurf is indicated in combination with bevacizumab for the treatment of adult 
patients with metastatic colorectal cancer (CRC) who have received two prior 
anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-
based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. 
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal 
cancer who have been previously treated with, or are not considered candidates for, available 
therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-
VEGF agents, and anti-EGFR agents. 
Gastric cancer 
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric 
cancer including adenocarcinoma of the gastroesophageal junction, who have been previously 
treated with at least two prior systemic treatment regimens for advanced disease (see section 
5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
the marketing authorisation has been granted by the European Commission. 
Lonsurf  
EMA/CHMP/263819/2023 
Page 2/2 
 
 
 
 
